Profile for Karyopharm Therapeutics Inc. (KPTI)
« Back to company indexKPTI Chatter Timeline
Stock Ticker for KPTI
Most Active Tweeters for KPTI
| User | Tweets |
|---|---|
| @confcalltran | 7 |
| @Biotech2050 | 6 |
| @SleekMoneycom | 5 |
| @intercooleronli | 5 |
| @CFinancialNews | 5 |
Recent Tweets for KPTI
 |
@SPNewsAnalysis Karyopharm Therapeutics Inc. Expected to Earn FY2020 Earnings of $0.02 Per Share $KPTI https://t.co/kzxssyglCp September 23rd 2017, 12:09pm |
 |
@Primiano RT @Karyopharm: $KPTI Appoints Michael Falvey as CFO, Adds Clinical Strategy & Human Resources Executives & Reports Inducement Grant https:… September 23rd 2017, 12:09am |
 |
@WatchlistN Karyopharm Therapeutics Inc. $KPTI Receives Average Rating of “Buy” from Brokerages https://t.co/JJKv1OWpYv September 22nd 2017, 6:09pm |
 |
@tom_mcdaniels $kpti presenting at cantor on Monday. Expect updated roadmap and SEAL results September 22nd 2017, 2:09pm |
 |
@CFinancialNews Wedbush Weighs in on Karyopharm Therapeutics Inc.’s FY2020 Earnings $KPTI https://t.co/jT3wWDAazo September 22nd 2017, 1:09pm |
 |
@intercooleronli Wedbush Weighs in on Karyopharm Therapeutics Inc.’s FY2020 Earnings $KPTI https://t.co/BlqBO1d7r9 September 22nd 2017, 1:09pm |
 |
@finboxio Mirza (Director) sold 2,882 shares of $KPTI. Yes... stock's above fair value https://t.co/hkGT0txMYR https://t.co/6Fi6lDlaXW September 22nd 2017, 1:09pm |
 |
@1stOncology Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating #Selinexor in #Liposarcoma $KPTI https://t.co/kH3qY4TT0b September 22nd 2017, 10:09am |
 |
@SleekMoneycom Karyopharm Therapeutics Inc. $KPTI Rating Reiterated by Cantor Fitzgerald https://t.co/Z2CEDweLMl September 22nd 2017, 7:09am |
 |
@storminvestor Karyopharm Therapeutics Inc. $KPTI Rating Reiterated by Cantor Fitzgerald https://t.co/81qBGNut7Q September 22nd 2017, 1:09am |
|
@SPNewsAnalysis Karyopharm Therapeutics Inc. $KPTI Rating Reiterated by Cantor Fitzgerald https://t.co/BlytfvP9s8 September 22nd 2017, 1:09am |
|
@SleekMoneycom Royal Bank Of Canada Initiates Coverage on Karyopharm Therapeutics Inc. $KPTI https://t.co/8aYagUQxK6 September 21st 2017, 5:09pm |
 |
@kuritzmike RT @tgtxdough: LR $KPTI ahead of potentially registration-enabling Phase II results in "penta-refractory" multiple myeloma 1Q18. Raising PT… September 21st 2017, 4:09pm |
|
@intercooleronli Karyopharm Therapeutics Inc. $KPTI Earns Buy Rating from Cantor Fitzgerald https://t.co/McAKiHYKRK September 21st 2017, 3:09pm |
|
@CFinancialNews Karyopharm Therapeutics Inc. $KPTI Earns Buy Rating from Cantor Fitzgerald https://t.co/QkpOs9f1zy September 21st 2017, 3:09pm |
 |
@TheMarketsDaily Karyopharm Therapeutics’ $KPTI Buy Rating Reaffirmed at Cantor Fitzgerald https://t.co/9ldGaqltJr September 21st 2017, 2:09pm |
 |
@dakotafinancial Karyopharm Therapeutics’ $KPTI Buy Rating Reaffirmed at Cantor Fitzgerald https://t.co/hXx0yB0nO9 September 21st 2017, 2:09pm |
 |
@RatingsNetwork Karyopharm Therapeutics's buy rating reiterated at Cantor Fitzgerald. $18.00 PT. https://t.co/iu7Ud79agi $KPTI #KPTI September 21st 2017, 2:09pm |
 |
@Biotech2050 RT @tgtxdough: $KPTI KEY -STORM (penta-refractory MM) data Apr'18 w/ potential accelerated approval filing 2H18; final SADAL (DLBCL) analys… September 21st 2017, 1:09pm |
|
@Biotech2050 RT @tgtxdough: $KPTI three KOL events KOLs with MM-focused backgrounds (scheduled for Sep 27th in Boston Oct 3rd in NYC), on Oct 17th in NY… September 21st 2017, 1:09pm |
 |
@tgtxdough $KPTI KEY -STORM (penta-refractory MM) data Apr'18 w/ potential accelerated approval filing 2H18; final SADAL (DLBCL) analysis expected 2H18 September 21st 2017, 1:09pm |
|
@tgtxdough $KPTI three KOL events KOLs with MM-focused backgrounds (scheduled for Sep 27th in Boston Oct 3rd in NYC), on Oct 17th in NYC). September 21st 2017, 1:09pm |
 |
@AvisolCapital $KPTI positive results from phase 2/3 - https://t.co/YYSSaU3J5c September 21st 2017, 11:09am |
|
@TheMarketsDaily Karyopharm Therapeutics Inc. $KPTI SVP Sells $22,000.00 in Stock https://t.co/xsx1yzEr0G September 21st 2017, 11:09am |
 |
@emq_news Karyopharm Therapeutics Inc. $KPTI Director Sells $31,702.00 in Stock https://t.co/qpFgLWZNC0 September 21st 2017, 10:09am |
 |
@elfaulder9 RT @ChimeraResearch: September 21 Biotech Update $FOLD $kpti https://t.co/CodpXurqlO September 21st 2017, 9:09am |
 |
@ChimeraResearch September 21 Biotech Update $FOLD $kpti https://t.co/CodpXurqlO September 21st 2017, 9:09am |
 |
@tradejas RT @BioStocks: $KPTI Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor https://t.co/t80IVdJpCQ September 20th 2017, 9:09pm |
 |
@BadGoldClothlng RT @marketexclusive: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Files An 8-K Financial Statements and Exhibits https://t.co/gXeXtmqWAw $KPTI September 20th 2017, 8:09pm |
 |
@marketexclusive Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Files An 8-K Financial Statements and Exhibits https://t.co/gXeXtmqWAw $KPTI September 20th 2017, 8:09pm |
 |
@TickerReport Karyopharm Therapeutics Inc. $KPTI Sees Strong Trading Volume https://t.co/oUmPT0iIo4 September 20th 2017, 7:09pm |
|
@emq_news Karyopharm Therapeutics Inc. $KPTI Sees Strong Trading Volume https://t.co/zwO4518RYp September 20th 2017, 7:09pm |
|
@TickerReport Karyopharm Therapeutics Inc. $KPTI Sees Strong Trading Volume https://t.co/3g6XdkLkSI September 20th 2017, 7:09pm |
 |
@realmaciej RT @tgtxdough: JMP $KPTI PT 22 Selinexor for liposarcoma is not currently in our financial model. top-line Phase III SEAL results by the en… September 20th 2017, 4:09pm |
 |
@confcalltran Karyopharm Therapeutics: Targeting Disease At The Nuclear Pore https://t.co/i4PdfPeS4r $KPTI September 20th 2017, 4:09pm |
|
@tgtxdough JMP $KPTI PT 22 Selinexor for liposarcoma is not currently in our financial model. top-line Phase III SEAL results by the end of 2018 September 20th 2017, 2:09pm |
|
@tom_mcdaniels $kpti next up #ash2017 September 20th 2017, 1:09pm |
 |
@avidresearch $KPTI PFS using WHO criteria doesn't look that impressive. HR of 0.84 just 16% reduction. September 20th 2017, 11:09am |
 |
@tstamm7002 $KPTI incapable of holding gains September 20th 2017, 11:09am |
 |
@Mahmissa Ha! Evidently 42 shares filled on my $kpti short at 11.90 September 20th 2017, 9:09am |
 |
@SwingTradeBot Recent $KPTI technical alerts: Slingshot Bullish plus 2 more alerts... https://t.co/51Rgrexboy September 20th 2017, 9:09am |
 |
@StocksThatGo ALERT: NEWS $KPTI Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated September 20th 2017, 9:09am |
 |
@1MinuteStock Wondering about risks of $KPTI? The 63-day volatility is 22.22% https://t.co/CTFgRoQnqM September 20th 2017, 9:09am |
 |
@7LadyQ $KPTI Karyopharm's selinexor successful in mid-stage soft tissue cancer study; shares ahead 15% premarket September 20th 2017, 9:09am |
 |
@NewsToDesk $KPTI: Karyopharm’s selinexor successful in mid-stage soft tissue cancer …: https://t.co/xoTQgVAzZ7 September 20th 2017, 9:09am |
 |
@Anto_Casadei Karyopharm's selinexor successful in mid-stage soft tissue cancer study; shares ahead 15% premarket $KPTI https://t.co/nQBFieOkvL September 20th 2017, 9:09am |
 |
@SEEKINGALPHA_FS Karyopharm's selinexor successful in mid-stage soft tissue cancer study; shares ahead 15% premarket https://t.co/upJE9wFaqE #premarket $KPTI September 20th 2017, 9:09am |
 |
@MarketCurrents Karyopharm's selinexor successful in mid-stage soft tissue cancer study; shares ahead 15% premarket https://t.co/5InRdgBxSI #premarket $KPTI September 20th 2017, 9:09am |
 |
@MarketChmln $KPTI stock increases 14.1% in premarket, company press release at 7:00 AM https://t.co/gOJyOMG1ak September 20th 2017, 9:09am |
 |
@ARatings Karyopharm Therapeutics Received its Third Buy in a Row $KPTI https://t.co/xNdr2SdIyJ September 20th 2017, 8:09am |
Contact © thinkBiotech LLC 2004 - 2017. All rights reserved.